These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34991700)

  • 21. Antimicrobial susceptibility and molecular characterisation using whole-genome sequencing of
    Aoki K; Takeda S; Miki T; Ishii Y; Tateda K
    Antimicrob Agents Chemother; 2019 Sep; 63(12):. PubMed ID: 31527041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China.
    Cheng JW; Yang QW; Xiao M; Yu SY; Zhou ML; Kudinha T; Kong F; Liao JW; Xu YC
    J Microbiol Immunol Infect; 2018 Jun; 51(3):411-416. PubMed ID: 28693926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective, observational study of fidaxomicin use for
    Guery B; Berger P; Gauzit R; Gourdon M; Barbut F; ; Dafne Study Group ; Bémer P; Bessède E; Camou F; Cattoir V; Couzigou C; Descamps D; Dinh A; Laurans C; Lavigne JP; Lechiche C; Leflon-Guibout V; Le Monnier A; Levast M; Mootien JY; N'Guyen Y; Piroth L; Prazuck T; Rogeaux O; Roux AL; Vachée A; Vernet Garnier V; Wallet F
    J Int Med Res; 2021 Jun; 49(6):3000605211021278. PubMed ID: 34162264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Tapered-pulsed Fidaxomicin Regimen Following Treatment in Patients With Multiple Clostridioides difficile Infection Recurrences.
    Skinner AM; Tan X; Sirbu BD; Danziger LH; Gerding DN; Johnson S
    Clin Infect Dis; 2021 Sep; 73(6):1107-1109. PubMed ID: 33714998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.
    Nelson RL; Suda KJ; Evans CT
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD004610. PubMed ID: 28257555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin.
    Thabit AK; Alam MJ; Khaleduzzaman M; Garey KW; Nicolau DP
    Ann Clin Microbiol Antimicrob; 2016 Apr; 15():22. PubMed ID: 27071986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
    Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Visualization of fidaxomicin association with the exosporium layer of Clostridioides difficile spores.
    Bassères E; Endres BT; Montes-Bravo N; Pérez-Soto N; Rashid T; Lancaster C; Begum K; Alam MJ; Paredes-Sabja D; Garey KW
    Anaerobe; 2021 Jun; 69():102352. PubMed ID: 33640461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria.
    Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
    Antimicrob Agents Chemother; 2012 May; 56(5):2493-503. PubMed ID: 22290948
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015-18.
    Putsathit P; Hong S; George N; Hemphill C; Huntington PG; Korman TM; Kotsanas D; Lahra M; McDougall R; McGlinchey A; Moore CV; Nimmo GR; Prendergast L; Robson J; Waring L; Wehrhahn MC; Weldhagen GF; Wilson RM; Riley TV; Knight DR
    J Antimicrob Chemother; 2021 Jun; 76(7):1815-1821. PubMed ID: 33895826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.
    Ajami NJ; Cope JL; Wong MC; Petrosino JF; Chesnel L
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463537
    [No Abstract]   [Full Text] [Related]  

  • 32. The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin.
    Yamaguchi T; Konishi H; Aoki K; Ishii Y; Chono K; Tateda K
    J Infect Chemother; 2020 May; 26(5):483-491. PubMed ID: 32165071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance.
    Shah D; Dang MD; Hasbun R; Koo HL; Jiang ZD; DuPont HL; Garey KW
    Expert Rev Anti Infect Ther; 2010 May; 8(5):555-64. PubMed ID: 20455684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection.
    Zhanel GG; Walkty AJ; Karlowsky JA
    Can J Infect Dis Med Microbiol; 2015; 26(6):305-12. PubMed ID: 26744587
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frontiers in antibiotic alternatives for
    Phanchana M; Harnvoravongchai P; Wongkuna S; Phetruen T; Phothichaisri W; Panturat S; Pipatthana M; Charoensutthivarakul S; Chankhamhaengdecha S; Janvilisri T
    World J Gastroenterol; 2021 Nov; 27(42):7210-7232. PubMed ID: 34876784
    [No Abstract]   [Full Text] [Related]  

  • 36. Antimicrobial susceptibility of Clostridioides difficile isolated from diarrhoeal stool specimens of Canadian patients: summary of results from the Canadian Clostridioides difficile (CAN-DIFF) surveillance study from 2013 to 2017.
    Karlowsky JA; Adam HJ; Baxter MR; Dutka CW; Nichol KA; Laing NM; Golding GR; Zhanel GG
    J Antimicrob Chemother; 2020 Jul; 75(7):1824-1832. PubMed ID: 32294172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin.
    Leeds JA; Sachdeva M; Mullin S; Barnes SW; Ruzin A
    J Antimicrob Chemother; 2014 Jan; 69(1):41-4. PubMed ID: 23887866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-life experience with fidaxomicin in Clostridioides difficile infection: a multicentre cohort study on 244 episodes.
    Escudero-Sánchez R; Valencia-Alijo A; Cuéllar Tovar S; Merino-de Lucas E; García Fernández S; Gutiérrez-Rojas Á; Ramos-Martínez A; Salavert Lletí M; Castro Hernández I; Giner L; Cobo J
    Infection; 2021 Jun; 49(3):475-482. PubMed ID: 33417171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin Production.
    Chilton CH; Crowther GS; Ashwin H; Longshaw CM; Wilcox MH
    PLoS One; 2016; 11(8):e0161200. PubMed ID: 27556739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the in vitro antibacterial activity of Ramizol, fidaxomicin, vancomycin, and metronidazole against 100 clinical isolates of Clostridium difficile by broth microdilution.
    Wolfe C; Pagano P; Pillar CM; Shinabarger DL; Boulos RA
    Diagn Microbiol Infect Dis; 2018 Nov; 92(3):250-252. PubMed ID: 30042035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.